Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Global Market Report 2025

The increasing prevalence of cervical cancer is expected to drive the growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market. Cervical cancer, a malignant tumor that develops in the cervix, the lower part of the uterus that connects to the vagina, is primarily rising due to persistent infections with high-risk strains of HPV. These infections cause abnormal changes in cervical cells that can develop into cancer if not detected and treated early. HPV and CMV therapeutics play a vital role in managing cervical cancer by targeting the virus-driven disease progression and improving patient outcomes. They help reduce the risk of cancer by providing antiviral treatments and immunotherapies that enhance long-term health and quality of life. For example, a report by the American Cancer Society in April 2024 revealed that approximately 20 million new cervical cancer cases were diagnosed globally in 2022, with projections showing this number could rise to 35 million by 2050. This increasing prevalence of cervical cancer is propelling the growth of the HPV and CMV therapeutic market.

Leading companies in the HPV and CMV therapeutics market are focusing on the development of innovative solutions, such as post-transplant anti-cytomegalovirus (CMV) treatments, to address unmet medical needs, enhance treatment efficacy, reduce resistance to existing therapies, and improve outcomes for immunocompromised patients. Post-transplant anti-CMV treatments are designed to prevent or manage CMV infections in organ or stem cell transplant recipients who are at high risk due to immunosuppression. For instance, in June 2024, Takeda Pharmaceutical Company Limited, based in Japan, received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for LIVTENCITY (maribavir) to treat post-transplant CMV infections or diseases that are resistant to current anti-CMV medications. This innovative antiviral agent is the only treatment in Japan that specifically targets and inhibits the cytomegalovirus (CMV)-specific UL97 protein kinase, offering a new mechanism of action distinct from traditional therapies.

In May 2022, Cheplapharm Arzneimittel GmbH, a pharmaceutical company based in Germany, acquired the rights to Valcyte from F. Hoffmann-La Roche AG. With this acquisition, Cheplapharm aims to expand its antiviral portfolio by adding Valcyte, a drug primarily used to treat cytomegalovirus (CMV) infections in transplant patients. F. Hoffmann-La Roche AG, a healthcare and pharmaceutical company based in Switzerland, specializes in developing and marketing Valcyte for CMV infections.

Major players in the human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline (GSK) plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Cepheid Inc., QIAGEN N.V., Vir Biotechnology Inc., Meridian Bioscience Inc.

North America was the largest region in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market consists of revenues earned by entities providing specific services such as antiviral drug infusion and dispensing, therapeutic vaccine administration, genotypic resistance testing, viral load monitoring, patient counselling and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market also includes sales of antiviral medications, therapeutic vaccines targeting human papillomavirus strains, immunomodulators, monoclonal antibodies, and gene therapy-based treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.